acut
respiratori
tract
infect
associ
increas
risk
acut
ischem
heart
diseas
stroke
venou
thromboembol
transient
chang
local
hemodynam
factor
coagul
activ
reduc
gener
anticoagul
activ
protein
c
apc
inhibit
fibrinolysi
endotheli
cell
perturb
result
system
inflamm
might
underli
mechan
inde
shown
respiratori
virus
abl
activ
coagul
caus
reduct
clot
time
increas
express
tissu
factor
thrombin
gener
latter
reduc
level
protein
c
also
increas
level
hemostat
protein
symptom
acut
respiratori
tract
infect
shown
endotheli
cell
perturb
increas
level
hemostat
marker
von
willebrand
factor
vwf
ddimer
complex
pap
plasminogen
activ
risk
factor
ischem
heart
diseas
high
vwf
level
also
relat
shortterm
increas
risk
plaqu
ruptur
subsequ
thrombu
format
recent
shown
respiratori
tract
infect
elderli
human
subject
result
increas
level
vwf
pap
complex
thu
procoagul
state
present
studi
examin
effect
natur
occur
acut
respiratori
tract
infect
hemostat
protein
detail
prospect
cohort
studi
includ
men
women
year
older
gener
offic
winter
patient
infect
influenzalik
ill
ili
definit
describ
previous
within
week
recruit
exclud
institut
review
board
approv
studi
subject
provid
inform
consent
detail
medic
histori
blood
sampl
obtain
entri
case
ili
blood
sampl
throat
swab
obtain
within
day
repeat
day
later
day
acut
phase
blood
collect
process
describ
previous
highsensit
crp
hscrp
measur
use
synchron
lx
system
beckman
coulter
fullerton
usa
prothrombin
fragment
elisa
siemen
healthcar
diagnost
marburg
germani
pap
complex
elisa
drg
marburg
germani
activ
assay
behr
coagul
system
siemen
healthcar
diagnost
ddimer
measur
particleenhanc
immunoturbidimetr
assay
innov
ddimer
siemen
healthcar
diagnost
vwf
use
homemad
immunoassay
employ
antibodi
dako
glostrup
denmark
result
vwf
present
percentag
normal
pool
plasma
gener
thrombin
clot
plasma
assay
calibr
autom
thrombogram
describ
hemker
et
al
coagul
trigger
recalcif
presenc
pm
recombin
human
tissu
factor
innovin
siemen
healthcar
diagnost
lm
phospholipid
lm
fluorogen
substrat
zglyglyargamc
bachem
bubendorf
switzerland
fluoresc
monitor
use
fluoroskan
ascent
fluoromet
thermolabsystem
helsinki
finland
endogen
thrombin
potenti
etp
peak
thrombin
time
peak
lag
time
veloc
index
calcul
use
thrombinoscop
softwar
thrombinoscop
bv
maastricht
netherland
sensit
activ
protein
c
apc
enzym
research
laboratori
south
bend
usa
plasma
sampl
determin
presenc
absenc
approxim
nm
apc
apc
concentr
use
adjust
maintain
residu
thrombin
gener
activ
approxim
normal
pool
plasma
normal
pool
plasma
run
parallel
plate
normal
ratio
apcsr
determin
divid
apcsr
individu
apcsr
pool
plasma
normal
apcsr
reflect
apcresist
phenotyp
presenc
iga
igg
antibodi
influenza
b
parainfluenza
respiratori
syncyti
viru
rsv
adenoviru
specif
igm
igg
mycoplasma
pneumonia
establish
use
elisa
serionviron
germani
throat
swab
test
mean
previous
describ
realtim
pcr
respiratori
syncyti
consid
recent
respiratori
tract
proven
posit
specif
iga
igm
fourfold
elev
specif
igg
result
sampl
taken
first
day
ill
week
later
result
pcr
throat
swab
sampl
posit
data
present
median
interquartil
rang
iqr
variabl
compar
use
sign
rank
test
pvalu
consid
statist
signific
fifteen
subject
contact
us
ili
eleven
infect
found
subject
influenza
influenza
b
adenoviru
coronaviru
nl
coronaviru
mycoplasma
pneumonia
one
subject
simultan
infect
influenza
coronaviru
five
subject
caus
pathogen
could
found
subject
fulfil
clinic
criteria
ili
significantli
increas
level
hscrp
acut
phase
compar
baselin
tabl
acut
phase
observ
signific
increas
level
vwf
pap
ddimer
compar
baselin
wherea
chang
ddimer
level
also
statist
increas
convalesc
phase
compar
baselin
wherea
vwf
pap
level
almost
return
baselin
level
paramet
thrombin
gener
etp
peak
thrombin
veloc
index
show
signific
procoagul
chang
infect
period
remain
even
convalesc
phase
also
infect
result
acquir
apc
resist
persist
convalesc
phase
obviou
men
explain
apc
resist
obviou
men
persist
apc
resist
might
explain
elev
level
factor
f
viii
decreas
level
protein
howev
vwf
return
baselin
fviii
would
expect
normal
well
level
remain
differ
convalesc
phase
clear
present
find
show
hemostat
system
affect
number
way
acut
phase
respiratori
tract
infect
first
significantli
elev
level
vwf
indic
activ
endothelium
second
significantli
elev
level
pap
ddimer
indic
increas
fibrinolysi
third
chang
increas
ex
vivo
thrombin
gener
etp
enhanc
resist
apc
suggest
procoagul
state
infect
find
correl
similar
studi
perform
earlier
group
other
report
similar
chang
hemostat
marker
patient
flulik
symptom
studi
infect
confirm
object
analysi
nonelev
level
prothrombin
fragment
suggest
enhanc
vivo
thrombin
format
howev
significantli
elev
etp
suggest
potenti
increas
thrombin
format
therefor
procoagul
state
acut
phase
respiratori
tract
infect
increas
level
ddimer
indic
enhanc
vivo
thrombin
format
may
part
result
enhanc
fibrinolysi
observ
appar
paradox
ddimer
may
also
explain
shorter
halflif
compar
ddimer
subject
control
factor
could
influenc
hemostat
protein
preexist
condit
tabl
hscrp
high
sensit
creactiv
protein
vwf
von
willebrand
factor
prothrombin
fragment
pap
plasmina
antiplasmin
complex
pai
plasminogen
activ
vel
index
veloc
index
etp
endogen
thrombin
potenti
apcsr
activ
protein
csensit
ratio
significantli
differ
baselin
p
tendenc
toward
signific
differ
p
one
patient
use
oral
anticoagul
exclud
analysi
letter
editor
medic
exclud
fact
level
hemostat
protein
crp
almost
return
baselin
week
initi
diseas
episod
indic
unlik
observ
increas
result
season
variat
howev
result
design
studi
effect
season
variat
exclud
conclus
present
studi
show
natur
occur
respiratori
tract
infect
human
subject
result
endotheli
cell
perturb
vwf
increas
fibrinolyt
state
pap
ddimer
potenti
increas
coagul
etp
apcsr
vwf
pap
complex
etp
resist
apc
suggest
increas
risk
ischem
heart
diseas
venou
thromboembol
suggest
induc
hemostat
chang
may
form
link
acut
respiratori
tract
infect
acut
atherothrombot
diseas
precis
relat
risk
still
need
establish
larg
prospect
studi
